KTTA Stock Analysis: Buy, Sell, or Hold?
KTTA - Pasithea Therapeutics Corp. Common Stock
$0.67
-0.02 (-2.30%)
▼
5d:
-2.3%
30d:
-8.91%
90d:
-20.39%
HOLD
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 21, 2026
21d
Get Alerted When KTTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KTTA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: KTTA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: KTTA is currently trading at $0.67, which is considered oversold relative to its 30-day fair value range of $0.70 to $0.77.
Technical Outlook: Technically, KTTA is in a strong downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KTTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+345.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KTTA is in a strong downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KTTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $3.00 (+345.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.70 -
$0.77
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 345.0% below Wall St target ($3.00)
Trading Range Analysis
30-Day Trading Range
$0.70 -
$0.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.67
Resistance Level
$0.79
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.32
Wall Street Target
$3.00
(+345.0%)
Revenue Growth (YoY)
1498.1%
Share & Embed Analysis
Last updated: April 29, 2026 2:38 AM ET
Data refreshes hourly during market hours. Next update: 3:38 AM
Data refreshes hourly during market hours. Next update: 3:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KTTA showing a specific setup today?
Insider Activity (6 Months)
3
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Lawrence Steinman
BUY
133333 shares
2025-11-28
Simon Dumesnil
BUY
33333 shares
2025-11-28
Tiago Marques
BUY
33333 shares
2025-11-28
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$408 | 52 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$224 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$298 | 58 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 57 HOLD |
